NCT00301873View on ClinicalTrials.gov

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2011

Study Completion Date

September 30, 2012

Conditions
Brain TumorsOsteoporosisCentral Nervous System(CNS)Malignancies
Interventions
DRUG

IV Zometa

Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Duke University

OTHER

NCT00301873 - Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma | Biotech Hunter | Biotech Hunter